Table 2. Clinical data for hepatitis C... | Rockefeller University Press

Table 2.

Clinical data for hepatitis C patients treated with IFN-α

n	IFN-α treatment (+)
n	1,115
Time from initiation of IFN treatment to blood collection (years)
<1	297
1–5	364
6–10	179
11–15	112
16–20	83
>20	18
Unknown	62
No. of treatment lines
First line	673
Second line	256
Third line	101
Fourth line	48
>Fifth line	37
Unknown	0
Prior treatment with IFNβ	119
Total duration of IFN treatment (months)
0–3	91
4–6	294
7–12	193
13–18	124
19–24	51
25–30	37
31–36	17
>37	45
Unknown	263
Source of IFN-α2 preparations
Native IFN-α2 alone	127
Recombinant IFN-α2 alone	746
Both native and recombinant IFN-α2	242
Ribavirin co-administration
Yes	563
No	552

n	IFN-α treatment (+)
n	1,115
Time from initiation of IFN treatment to blood collection (years)
<1	297
1–5	364
6–10	179
11–15	112
16–20	83
>20	18
Unknown	62
No. of treatment lines
First line	673
Second line	256
Third line	101
Fourth line	48
>Fifth line	37
Unknown	0
Prior treatment with IFNβ	119
Total duration of IFN treatment (months)
0–3	91
4–6	294
7–12	193
13–18	124
19–24	51
25–30	37
31–36	17
>37	45
Unknown	263
Source of IFN-α2 preparations
Native IFN-α2 alone	127
Recombinant IFN-α2 alone	746
Both native and recombinant IFN-α2	242
Ribavirin co-administration
Yes	563
No	552

Sharing Unavailable